中国药业
中國藥業
중국약업
CHINA PHARMACEUTICALS
2014年
14期
25-28,29
,共5页
白细胞介素-2%顺铂%恶性胸腔积液%Meta分析
白細胞介素-2%順鉑%噁性胸腔積液%Meta分析
백세포개소-2%순박%악성흉강적액%Meta분석
interleukin - 2%cisplatin%malignant pleural effusion%meta analysis
目的：评价胸腔注射白细胞介素-2对比顺铂治疗恶性胸腔积液的有效性和安全性。方法计算机检索 Cochrane Library，Pubmed， Embase、中国生物医学文献数据库、中国期刊全文数据库、维普中文科技期刊全文数据库和万方数据库，对符合纳入标准的随机对照试验进行方法学质量评价，采用 RevMan 5.2.6进行 Meta 分析。结果共纳入11个研究543例患者。Meta 分析结果显示，胸腔注射白细胞介素-2治疗恶性胸腔积液的有效率（ RR =1.24，95% CI[1.10，1.40]，P =0.0006）、完全缓解率（ RR =1.33，95% CI[1.04，1.71]， P =0.02）、发热发生率（ RR =2.07，95% CI[1.44，2.96]，P ﹤0.0001）高于顺铂，而胸痛（ RR =0.34，95% CI[0.14，0.84]，P =0.02）、骨髓抑制（ RR =0.05，95% CI[0.02，0.16]，P ﹤0.00001）、消化道反应（ RR =0.20，95% CI[0.13，0.30]，P ﹤0.00001）的发生率低于顺铂。结论胸腔注射白细胞介素-2治疗恶性胸腔积液的疗效优于顺铂，且不良反应较顺铂少，需注意较易导致发热。
目的：評價胸腔註射白細胞介素-2對比順鉑治療噁性胸腔積液的有效性和安全性。方法計算機檢索 Cochrane Library，Pubmed， Embase、中國生物醫學文獻數據庫、中國期刊全文數據庫、維普中文科技期刊全文數據庫和萬方數據庫，對符閤納入標準的隨機對照試驗進行方法學質量評價，採用 RevMan 5.2.6進行 Meta 分析。結果共納入11箇研究543例患者。Meta 分析結果顯示，胸腔註射白細胞介素-2治療噁性胸腔積液的有效率（ RR =1.24，95% CI[1.10，1.40]，P =0.0006）、完全緩解率（ RR =1.33，95% CI[1.04，1.71]， P =0.02）、髮熱髮生率（ RR =2.07，95% CI[1.44，2.96]，P ﹤0.0001）高于順鉑，而胸痛（ RR =0.34，95% CI[0.14，0.84]，P =0.02）、骨髓抑製（ RR =0.05，95% CI[0.02，0.16]，P ﹤0.00001）、消化道反應（ RR =0.20，95% CI[0.13，0.30]，P ﹤0.00001）的髮生率低于順鉑。結論胸腔註射白細胞介素-2治療噁性胸腔積液的療效優于順鉑，且不良反應較順鉑少，需註意較易導緻髮熱。
목적：평개흉강주사백세포개소-2대비순박치료악성흉강적액적유효성화안전성。방법계산궤검색 Cochrane Library，Pubmed， Embase、중국생물의학문헌수거고、중국기간전문수거고、유보중문과기기간전문수거고화만방수거고，대부합납입표준적수궤대조시험진행방법학질량평개，채용 RevMan 5.2.6진행 Meta 분석。결과공납입11개연구543례환자。Meta 분석결과현시，흉강주사백세포개소-2치료악성흉강적액적유효솔（ RR =1.24，95% CI[1.10，1.40]，P =0.0006）、완전완해솔（ RR =1.33，95% CI[1.04，1.71]， P =0.02）、발열발생솔（ RR =2.07，95% CI[1.44，2.96]，P ﹤0.0001）고우순박，이흉통（ RR =0.34，95% CI[0.14，0.84]，P =0.02）、골수억제（ RR =0.05，95% CI[0.02，0.16]，P ﹤0.00001）、소화도반응（ RR =0.20，95% CI[0.13，0.30]，P ﹤0.00001）적발생솔저우순박。결론흉강주사백세포개소-2치료악성흉강적액적료효우우순박，차불량반응교순박소，수주의교역도치발열。
Objective To compare the effectiveness and safety of intrapleural interleukin - 2 and cisplatin for treating malignant pleural effusion. Methods Seven databases were performed the computer retrieval,including Cochrane Library,Pubmed,Embase,CBM,CNKI,VIP and Wanfang database. The methodological quality assessment of included randomized controlled trials(RCTs) were conducted according to the methods of Cochrane Collaboration. Meta analysis was performed using the RevMan5. 2. 6 software. Results A total of 11 RCTs involving 543 patients were included. The Meta analysis results showed that intrapleural interleukin - 2 was higher than cisplatin for treating malignant pleural effusion in the aspects of the overall response rate( RR = 1. 24,95% CI[1. 10,1. 40],P = 0. 000 6),complete response rate( RR = 1. 33,95% CI[1. 04,1. 71],P = 0. 02)and fever occurrence rate( RR = 2. 07,95% CI[1. 44,2. 96],P ﹤ 0. 000 1), while the occurrence rate of pectoralgia( RR = 0. 34,95% CI [0. 14,0. 84],P = 0. 02),myelosuppression( RR = 0. 05,95% CI[0. 02, 0. 16],P ﹤ 0. 000 01)and gastrointestinal reaction( RR = 0. 20,95% CI[0. 13,0. 30],P ﹤ 0. 000 01)in interleukin - 2 were lower than those in cisplatin. Conclusion The effectiveness of intrapleural interleukin - 2 is superior to that of cisplatin for treating malignant pleural effusion,moreover its adverse reactions are less than those of cisplatin,but intrapleural interleukin - 2 is easy to cause fever, which needs to pay attention to.
